Legend Biotech (NASDAQ:CALT) Now Covered by Analysts at Stifel Nicolaus

Stifel Nicolaus assumed coverage on shares of Legend Biotech (NASDAQ:CALT) in a research report released on Tuesday morning, The Fly reports. The firm issued a buy rating and a $28.00 price objective on the stock.

NASDAQ CALT opened at $19.95 on Tuesday. Legend Biotech has a fifty-two week low of $19.00 and a fifty-two week high of $24.97.

Legend Biotech Company Profile

Calliditas Therapeutics AB (publ) operates as a biopharmaceutical company in Stockholm, Sweden. It focuses on identifying, developing, and commercializing pharmaceutical products for patients with unmet medical needs. The company's lead product candidate is Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area.

Recommended Story: How Do Tariffs Affect Trade Balances?

The Fly

Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.